The University of Chicago Header Logo

Connection

Yonglin Pu to Fluorodeoxyglucose F18

Back to Details
This is a "connection" page, showing publications Yonglin Pu has written about Fluorodeoxyglucose F18.
Yonglin Pu
Connection Strength
3.832
Fluorodeoxyglucose F18
  1. Comparison of Measurement and Prognostic Power of SUV Between High-Definition and Standard PET Imaging in Non-Small Cell Lung Cancer Patients. J Nucl Med Technol. 2024 Sep 05; 52(3):229-233.
    View in: PubMed
    Score: 0.814
  2. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times. Nucl Med Commun. 2016 Jan; 37(1):50-6.
    View in: PubMed
    Score: 0.446
  3. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images. Radiology. 2015 Jun; 275(3):862-9.
    View in: PubMed
    Score: 0.417
  4. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer. Acad Radiol. 2012 Jan; 19(1):69-77.
    View in: PubMed
    Score: 0.338
  5. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012 Jan; 39(1):27-38.
    View in: PubMed
    Score: 0.332
  6. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors. Acta Radiol. 2010 Sep; 51(7):782-8.
    View in: PubMed
    Score: 0.308
  7. FDG-PET/CT findings of a metastatic pituitary tumor. Cancer Imaging. 2010 Mar 18; 10:114-6.
    View in: PubMed
    Score: 0.299
  8. Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy. Front Biosci (Landmark Ed). 2022 01 12; 27(1):16.
    View in: PubMed
    Score: 0.169
  9. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2018 09; 123:136-141.
    View in: PubMed
    Score: 0.133
  10. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2079-2092.
    View in: PubMed
    Score: 0.132
  11. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer. Nucl Med Commun. 2017 Feb; 38(2):185-192.
    View in: PubMed
    Score: 0.120
  12. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2013 Jan; 20(1):32-40.
    View in: PubMed
    Score: 0.089
  13. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer. Acta Radiol. 2012 Jun 01; 53(5):561-8.
    View in: PubMed
    Score: 0.087
  14. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer. Int J Comput Assist Radiol Surg. 2013 Mar; 8(2):181-91.
    View in: PubMed
    Score: 0.087
  15. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
    View in: PubMed
    Score: 0.048
  16. Integrating PET and CT information to improve diagnostic accuracy for lung nodules: A semiautomatic computer-aided method. J Nucl Med. 2006 Jul; 47(7):1075-80.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.